Evidence map›Paper›PMID 35071653›Full record

ArticleOrthopaedic journal of sports medicine2022

Safety and Efficacy of Matrix-Associated Autologous Chondrocyte Implantation With Spheroids for Patellofemoral or Tibiofemoral Defects: A 5-Year Follow-up of a Phase 2, Dose-Confirmation Trial.

Arnd Hoburg, Philipp Niemeyer, Volker Laute, Wolfgang Zinser, Thilo John, Christoph Becher, Kaywan Izadpanah, Peter Diehl, Thomas Kolombe, Jakob Fay and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orthopaedic journal of sports medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01225575 (Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01225575 phase2completednot on this map

Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects(4-10 cm²) With 3 Diff. Doses of the ACT Product co.Don Chondrosphere®

TypeinterventionalSponsorco.don AGRan2010 to 2018Enrolled75ConditionsLarge Articular Cartilage Lesions of the Femoral, Condyle, Trochlea, Tibia or RetropatellarArmsco.don chondrosphere®
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Hyperplastic Human Macromass Cartilage for Joint Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Arnd HoburgMed Center 360° Berlin, Berlin, Germany.
Philipp NiemeyerDepartment of Orthopedic Surgery and Traumatology, Freiburg University Hospital, Germany and OCM Clinic, Munich, Germany.
Volker LauteMed Center 360° Berlin, Berlin, Germany.
Wolfgang ZinserDepartment of Orthopedic Surgery and Traumatology, St. Vinzenz Hospital, Dinslaken, Germany.
Thilo JohnClinic for Traumatology and Orthopedic Surgery, DRK Hospital Westend, Berlin, Germany.
Christoph BecherDepartment of Orthopaedic Surgery, Hannover Medical School, Diakovere Annastift, Hannover, Germany.
Kaywan IzadpanahDepartment of Orthopedic and Trauma Surgery, Freiburg University Hospital, Freiburg, Germany.
Peter DiehlDepartment of Orthopedic Surgery and Traumatology, Orthopedic Center Munich East, Munich, Germany.
Thomas KolombeTraumatology and Reconstructive Surgery, DRK Hospital, Luckenwalde, Germany.
Jakob FayDepartment of Traumatology and Arthroscopic Surgery, Lubinus Clinicum, Kiel, Germany.
Rainer SieboldCenter for Hip, Knee and Foot Surgery, ATOS Clinic, Heidelberg, Germany.
Stefan FickertSporthopaedicum, Straubing, Germany.
Diakovere · DEDRK Kliniken Berlin · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMatrix-associated autologous chondrocyte implantation (ACI) is a well-established treatment for cartilage defects. High-level evidence at midterm follow-up is limited, especially for ACI using spheroids (spherical aggregates of ex vivo expanded human autologous chondrocytes and self-synthesized extracellular matrix). PURPOSE: To assess the safety and efficacy of 3-dimensional matrix-associated ACI using spheroids to treat medium to large cartilage defects on different locations in the knee joint (patella, trochlea, and femoral condyle) at 5-year follow-up. STUDY

designCohort study; Level of evidence, 2.

methodsA total of 75 patients aged 18 to 50 years with medium to large (4-10 cm

resultsA total of 73 patients were treated: 24 in the low-dose group, 25 in the medium-dose group, and 24 in the high-dose group. The overall KOOS improved from 57.0 ± 15.2 at baseline to 73.4 ± 17.3 at 1-year follow-up (

conclusionACI using spheroids was safe and effective for defect sizes up to 10 cm REGISTRATION: NCT01225575 (ClinicalTrials.gov identifier); 2009-016816-20 (EudraCT number).

Indexed as

ACIcartilagekneepatellofemoralprospective randomized trialspheroidstibiofemoral

Identifiers

PMID35071653
PMCPMC8777354
OpenAlexW4206454628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.